Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

RNA Editing02:23

RNA Editing

9.7K
RNA editing is a post-transcriptional modification where a precursor mRNA (pre-mRNA) nucleotide sequence is changed by base insertion, deletion, or modification. The extent of RNA editing varies from a few hundred bases, in mitochondrial DNA of trypanosomes, to a just single base, in nuclear genes of mammals. Even a single base change in the pre-mRNA can convert a codon for one amino acid into the codon for another amino acid or a stop codon. This type of re-coding can significantly affect the...
9.7K
Experimental RNAi02:15

Experimental RNAi

7.2K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.2K
CRISPR/Cas9 Genome Editing01:28

CRISPR/Cas9 Genome Editing

1.5K
The CRISPR-Cas system serves as a bacterial defense mechanism against invading genetic elements such as viruses and plasmids, forming the foundation for its adaptation as a powerful genome-editing tool. Originally discovered in prokaryotes, this system has been repurposed to revolutionize genetic engineering across a wide range of organisms, including plants, animals, and humans. The core component, Cas9, is an endonuclease derived from Streptococcus pyogenes, capable of introducing...
1.5K
CRISPR01:59

CRISPR

57.3K
Genome editing technologies allow scientists to modify an organism’s DNA via the addition, removal, or rearrangement of genetic material at specific genomic locations. These types of techniques could potentially be used to cure genetic disorders such as hemophilia and sickle cell anemia. One popular and widely used DNA-editing research tool that could lead to safe and effective cures for genetic disorders is the CRISPR-Cas9 system. CRISPR-Cas9 stands for Clustered Regularly Interspaced...
57.3K
RNA Interference01:23

RNA Interference

27.6K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
27.6K
CRISPR and crRNAs02:53

CRISPR and crRNAs

18.6K
Bacteria and archaea are susceptible to viral infections just like eukaryotes; therefore, they have developed a unique adaptive immune system to protect themselves. Clustered regularly interspaced short palindromic repeats and CRISPR-associated proteins (CRISPR-Cas) are present in more than 45% of known bacteria and 90% of known archaea.
The CRISPR-Cas system stores a copy of foreign DNA in the host genome and uses it to identify the foreign DNA upon reinfection. CRISPR-Cas has three different...
18.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The oriGen case and Mexico's regulatory blind spots in genomic biobanking.

Trends in biotechnology·2026
Same author

Preventable mortality in Mexico: bridging gaps in chronic disease and ageing care.

BMJ global health·2026
Same author

Emerging cell surface glycoRNAs with potential regulatory roles.

Drug discovery today·2025
Same author

The roles and perspectives of YY1 in immune central tolerance establishment.

Biochimica et biophysica acta. Reviews on cancer·2025
Same author

The Regulatory Role of CTCF in IL6 Gene Transcription Assessed in Breast Cancer Cell Lines.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

Tackling 'lost in translation' issues: a response to Perez-Campos et al.

Trends in molecular medicine·2025

Related Experiment Video

Updated: Dec 28, 2025

A Nonsequencing Approach for the Rapid Detection of RNA Editing
08:50

A Nonsequencing Approach for the Rapid Detection of RNA Editing

Published on: April 21, 2022

2.9K

Novel Engineered Programmable Systems for ADAR-Mediated RNA Editing.

Guillermo Aquino-Jarquin1

  • 1Laboratorio de Investigación en Genómica, Genética y Bioinformática, Torre de Hemato-Oncología, 4to Piso, Sección 2, Hospital Infantil de México, Federico Gómez, Mexico City 06720, Mexico.

Molecular Therapy. Nucleic Acids
|February 12, 2020
PubMed
Summary

This article reviews four new technologies that use the body's own enzymes to fix genetic errors in RNA. By guiding these natural tools to specific locations, scientists can correct disease-causing mutations without changing the underlying DNA. These methods offer a promising, precise way to treat genetic conditions while avoiding permanent genomic alterations.

Keywords:
ADARRNA editingediting platformsgRNApoint mutationsRNA base editingCRISPR-Cas inspired systemstranscriptome engineeringtherapeutic gene correction

Frequently Asked Questions

More Related Videos

DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation
09:26

DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation

Published on: December 29, 2021

4.7K
Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms
09:51

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Published on: May 25, 2018

35.3K

Related Experiment Videos

Last Updated: Dec 28, 2025

A Nonsequencing Approach for the Rapid Detection of RNA Editing
08:50

A Nonsequencing Approach for the Rapid Detection of RNA Editing

Published on: April 21, 2022

2.9K
DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation
09:26

DNA-Tethered RNA Polymerase for Programmable In vitro Transcription and Molecular Computation

Published on: December 29, 2021

4.7K
Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms
09:51

Enhanced Genome Editing with Cas9 Ribonucleoprotein in Diverse Cells and Organisms

Published on: May 25, 2018

35.3K

Area of Science:

  • Molecular biology research within ADAR-mediated RNA editing systems
  • Genetic engineering and biotechnology advancements

Background:

No prior work had fully synthesized the rapid evolution of programmable RNA-editing platforms. That uncertainty drove the need to evaluate how natural enzymes are harnessed for therapeutic precision. Prior research has shown that adenosine-to-inosine conversion represents a common post-transcriptional modification. Scientists have long sought ways to direct these changes toward specific genetic targets. This gap motivated the development of systems that recruit endogenous enzymes to precise locations. Current literature highlights several distinct platforms designed for this exact purpose. These tools utilize guide molecules to direct enzymatic activity toward chosen transcripts. Such advancements represent a shift in how researchers approach the correction of point mutations.

Purpose Of The Study:

The aim of this review is to analyze the current status and rapid progress of novel ADAR-mediated RNA-editing systems. The author seeks to highlight the unique qualities of each recently engineered platform. This work addresses the need for a comprehensive overview of how these tools function in mammalian cells. The study explores how these strategies recruit human enzymes to endogenous transcripts. The author intends to clarify the potential of these systems for understanding gene expression regulation. This research also examines the capacity of these tools to correct clinically relevant mutations. The study provides a critical look at the challenges that must be addressed for future therapeutic use. The author aims to provide a clear perspective on the future of programmable RNA modification.

Main Methods:

The review approach involves a systematic analysis of four recently developed molecular platforms. The author evaluates the structural design and functional capabilities of each system. This examination focuses on how these tools recruit endogenous enzymes to specific target sequences. The analysis synthesizes data from studies conducted in various mammalian cell models. The author compares the programmability and efficiency of these distinct RNA-targeting strategies. This assessment highlights the mechanisms used to achieve precise base conversions. The review also considers the potential for correcting disease-associated mutations within full-length transcripts. Finally, the author discusses the current limitations regarding delivery and off-target activity.

Main Results:

Key findings from the literature indicate that these four platforms achieve precise base conversions in mammalian cells. The systems demonstrate high levels of programmability for targeting specific RNA transcripts. Research shows that these tools effectively recruit endogenous enzymes to perform adenosine-to-inosine modifications. The literature confirms that these methods allow for the correction of point mutations without modifying the host genome. Studies highlight that these platforms are capable of editing full-length transcripts with significant efficiency. The findings suggest that these tools provide a versatile alternative for in vivo research applications. The literature notes that while these systems are promising, off-target edits remain a challenge for current designs. The author reports that these strategies represent a major advancement in the field of RNA-based therapeutics.

Conclusions:

The authors propose that these platforms offer a versatile toolkit for precise genetic correction. They suggest that these systems effectively bypass the risks associated with permanent genomic alterations. The researchers note that the ability to target full-length transcripts remains a significant advantage for clinical utility. They highlight that overcoming off-target effects is necessary for future therapeutic implementation. The authors argue that these tools provide a straightforward method for studying gene regulation. They emphasize that delivery challenges must be resolved to enable widespread in vivo application. The researchers conclude that these systems represent a major step toward programmable molecular medicine. They maintain that continued refinement will likely improve the specificity of these editing strategies.

The researchers propose that these platforms function by recruiting endogenous adenosine deaminase acting on RNA enzymes to specific transcripts. This mechanism allows for precise base conversion without altering the underlying genomic sequence, distinguishing it from traditional gene-editing approaches that modify DNA directly.

The authors characterize four distinct platforms: CIRTS, RESCUE, RESTORE, and LEAPER. Each system utilizes unique guide architectures to direct enzymatic activity, providing researchers with diverse options for targeting specific sequences within mammalian cells.

The authors state that these systems are necessary for addressing disease-causing point mutations without permanent genomic changes. By targeting RNA rather than DNA, these tools avoid the risks of unintended, irreversible alterations to the host genome.

These platforms utilize guide molecules to recruit endogenous enzymes. This approach allows for the programmable modification of transcripts, offering a flexible alternative to methods that require the expression of exogenous, potentially immunogenic proteins.

The researchers measure success through the efficiency and specificity of base conversions. They emphasize that minimizing off-target edits is a key metric for evaluating the clinical potential of these tools compared to earlier, less precise methods.

The authors propose that these systems could eventually serve as therapeutic tools for treating genetic disorders. They suggest that once delivery and off-target challenges are resolved, these platforms may provide a viable path for correcting mutations in a clinical setting.